These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29757872)

  • 1. Pattern of Care, Health Care Disparities, and Their Impact on Survival Outcomes in Stage IVB Cervical Cancer: A Nationwide Retrospective Cohort Study.
    Jalloul RJ; Sharma S; Tung CS; O'Donnell B; Ludwig M
    Int J Gynecol Cancer; 2018 Jun; 28(5):1003-1012. PubMed ID: 29757872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer.
    Sasano T; Mabuchi S; Kuroda H; Takahashi R; Kozasa K; Isohashi F; Yoshioka Y; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2016 Mar; 26(3):528-33. PubMed ID: 26825839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
    Yin Z; Lou H; Tang H; Ni J; Zhou Q; Chen M
    Radiat Oncol; 2019 May; 14(1):82. PubMed ID: 31109371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
    Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
    Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer.
    Pradhan TS; Duan H; Katsoulakis E; Salame G; Lee YC; Abulafia O
    Int J Gynecol Cancer; 2011 Aug; 21(6):1091-6. PubMed ID: 21738045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
    Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
    Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive local therapy is associated with improved overall survival in metastatic cervical cancer.
    Venigalla S; Guttmann DM; Horne ZD; Carmona R; Shabason JE; Beriwal S
    Pract Radiat Oncol; 2018; 8(6):e377-e385. PubMed ID: 30174248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?
    Barrington DA; Dilley SE; Landers EE; Thomas ED; Boone JD; Straughn JM; McGwin G; Leath CA
    Gynecol Oncol; 2016 Dec; 143(3):617-621. PubMed ID: 27720232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
    Ramey SJ; Asher D; Kwon D; Ahmed AA; Wolfson AH; Yechieli R; Portelance L
    Gynecol Oncol; 2018 Apr; 149(1):53-62. PubMed ID: 29605051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical Cancer in Women Aged 35 Years and Younger.
    Pelkofski E; Stine J; Wages NA; Gehrig PA; Kim KH; Cantrell LA
    Clin Ther; 2016 Mar; 38(3):459-66. PubMed ID: 26899314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of paraaortic lymph nodes metastases in carcinoma of the cervix: analysis of treatment outcome.
    Plesinac-Karapandzic V; Zoranovic S; Tomasevic A; Radonjic M; Rakovic B; Nikitivic M; Cikaric S
    J BUON; 2006; 11(3):299-303. PubMed ID: 17309153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.
    Lea JS; Sheets EE; Wenham RM; Duska LR; Coleman RL; Miller DS; Schorge JO
    Gynecol Oncol; 2002 Jan; 84(1):115-9. PubMed ID: 11748986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.
    Wright JD; Huang Y; Ananth CV; Tergas AI; Duffy C; Deutsch I; Burke WM; Hou JY; Neugut AI; Hershman DL
    Gynecol Oncol; 2015 Dec; 139(3):506-12. PubMed ID: 26177552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma.
    Wong AT; Rineer J; Lee YC; Schwartz D; Safdieh J; Weiner J; Choi K; Schreiber D
    Gynecol Oncol; 2016 Sep; 142(3):514-9. PubMed ID: 27421751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ; Gardner JF; Seal B; Edelman MJ
    J Thorac Oncol; 2011 May; 6(5):934-41. PubMed ID: 21372743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributing factors for bone metastasis in uterine cervical cancer.
    Yoon A; Choi CH; Kim HJ; Park JY; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2013 Sep; 23(7):1311-7. PubMed ID: 23839246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-modality treatment in patients with advanced stage tonsil cancer.
    Roden DF; Schreiber D; Givi B
    Cancer; 2017 Sep; 123(17):3269-3276. PubMed ID: 28440876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.